Bioelectronics Corp (BIEL)

[srinsocal]

Hmmmm, The OTC Markets says that ENDV has been on the OTCQB Exchange for 4 and a half years.

I would agree that OTCQB opens up a larger investor pool than the Pink Sheets. However ENDV has only owned the patents to Sofpulse for 2 years so they did not upgrade Exchanges "to leave BIEL behind".

"OTCQB Member Since 06/2015"

https://www.otcmarkets.com/stock/ENDV/overview

IMO BIEL has nothing to fear from ENDV. They dug a deep financial hole when they purchased the Sofpulse Patents from Rio Grande for $4.5 Million in 12/2017. Since then they have had constant heavy dilution to pay for the purchase, seeing their SP plummet from .0649 to .0013 .

ENDV has had 2 Reverse Splits, in 5/2014 a 1 for 100 RS and in 12/2019 a 1 for 1000 RS.

In June of 2019 the ENDV's CEO Allan Collier announced a Sofpulse National Rollout which would involve 300 Sales Reps, make ENDV cash flow positive by the end of the year, and generate $300 million in sales in 2020.

This was a total BS Pump for his dilution machine. ENDV did $54k in sales according to their last financial statement, Q3 2019.

ENDV has done a couple of Pump PRs, giving out samples to NFL Teams, expanding into Plastic Surgery with no names mentioned, but never any dollar values given.

BIEL is Light Years ahead of ENDV, with FDA OTC Clearance, ENDV is prescription only, product cost of $29 for ActiPatch, $89 for RecoveryRx, vs $250 for Sofpulse.

https://www.globenewswire.com/news-release/2019/06/13/1868389/0/en/Endonovo-Therapeutics-Announces-National-Rollout-of-SofPulse-Post-Operative-Opioid-Alternative-into-Hospitals.html